Drugs
-
Lamotrigine (marketed as Lamictal) Information
Adverse reactions or quality problems experienced with the use of this Product may be reported to the FDA's MedWatch Adverse Event Reporting program either online, by regular mail or by fax, using the contact information at the bottom of this sheet.
-
Related Information
FDA Drug Safety Communication: Aseptic meningitis associated with use of Lamictal (lamotrigine)
8/12/2010FDA: Aseptic Meningitis Risk with Use of Seizure Drug Lamictal
FDA NEWS RELEASE - 8/12/2010FDA Drug Safety Podcast: Aseptic meningitis associated with use of Lamictal
8/2010FDA Drug Safety Podcast for Healthcare Professionals: Aseptic meningitis associated with use of Lamictal (lamotrigine)
8/2010Information for Healthcare Professionals: Suicidal Behavior and Ideation and Antiepileptic Drugs
1/31/2008Information for Healthcare Professionals: Lamotrigine (marketed as Lamictal)
9/2006 - Preliminary data from the North American Antiepileptic Drug Pregnancy Registry
-
-
Labeling and Regulatory History from Drugs@FDA
-
-
-